Romosozumab — getting there but not quite yet
Crossref DOI link: https://doi.org/10.1038/nrendo.2016.179
Published Online: 2016-11-04
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Papapoulos, Socrates E.
Text and Data Mining valid from 2016-11-04
Article History
First Online: 4 November 2016
Competing interests
: S.E.P. has received consulting and speaking fees from Amgen and UCB, and consulting fees from Mereo Biopharma.